Regadenoson Hydrate

Regadenoson hydrate was first approved by the U.S. Food and Drug Administration (FDA) on April 10, 2008, then approved by European Medicine Agency (EMA) on September 06, 2010. It was co-developed by Astellas and Rapidscan Pharma Solutions (RPS) EU Ltd, then marketed as Lexiscan® by Astellas in the US and as Rapiscan® by Rapidscan Pharma Solutions in EU.

Regadenoson is a low affinity agonist (Ki ≈ 1.3 μM) for the A2A adenosine receptor, with at least 10-fold lower affinity for the A1 adenosine receptor (Ki > 16.5 μM), and weak, if any, affinity for the A2B and A3 adenosine receptors. Activation of the A2A adenosine receptor by Regadenoson produces coronary vasodilation and increases coronary blood flow (CBF). It is indicated for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress.

Lexiscan® is available as injection solution for intravenous use, containing 0.4 mg/5 mL of free Regadenoson. The recommended dose is 5 mL (0.4 mg regadenoson) by rapid intravenous injection, followed immediately by saline flush and radiopharmaceutical.

Index：

General Information

Update Date：2016-05-13

Drug Name：
Regadenoson Hydrate
Research Code：
CVT-3146
Trade Name：
Lexiscan® / Rapiscan®
MOA：
A2A adenosine receptor agonist
Indication：
Myocardial perfusion imaging (MPI)
Status：
Approved
Company：
Astellas (Originator) , Rapidscan Pharma Solutions
Sales：
$599.1 Million (Y2014);
$585 Million (Y2013);
$572.3 Million (Y2012);
$536.7 Million (Y2011);
ATC Code：
C01EB21
Approved Countries or Area

Update Date：2015-07-29

Approval Date Approval Type Trade Name Indication Dosage Form Strength Company Review Classification
2008-04-10 Marketing approval Lexiscan Myocardial perfusion imaging (MPI) Injection, Solution Eq. 0.4 mg/5 mL Regadenoson Astellas
More
Approval Date Approval Type Trade Name Indication Dosage Form Strength Company Review Classification
2010-09-06 Marketing approval Rapiscan Myocardial perfusion imaging (MPI) Injection, Solution 400 μg Rapidscan Pharma Solutions
More
Chemical Structure

Update Date：2015-08-27

Molecular Weight 408.37
Formula C15H18N8O5 • H2O
CAS No. 313348-27-5 (Regadenoson);
875148-45-1 (Regadenoson Monohydrate);
Chemical Name 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]-adenosine, monohydrate
Regadenoson （Free Acid/Base）Parameters：
MW HD HA FRB* PSA* cLogP*
390.35 6 13 7 186 -1.244±0.636
*：Calculated by ACD/Labs software V11.02.
Related Patents

Update Date：2015-08-31

No. Major Technical Classification Publication No. Patent No. Legal Status Filling Date Estimated Expiry Date
1 Formula CN1358191A CN1167709C Granted 2000/6/21 2020/6/21
2 Uses CN1671399A Withdrawn 2003/7/29
3 Uses CN101076343A Withdrawn 2005/10/19
4 Preparation CN101379073A Refusal 2007/2/2
5 Preparation CN102260311A Refusal 2007/2/2
6 Preparation CN101668768A CN101668768B Granted 2007/5/17 2027/5/17
7 Combination CN101511366A CN101511366B Granted/abandoned 2007/8/31 2013/8/31
8 Combination CN102164591A Withdrawn 2009/9/29
More
Synthesis & Impurities

Update Date：2015-10-16


1. WO2014167046A1.

2. WO0078779A2.

3. Bioorg. Med. Chem. Lett. 2002, 12, 2935-2939.

4. J. Org. Chem. 1988, 53, 3051-3057.

5. J. Org. Chem. 1987, 52, 1344-1347.

6. Drugs of the Future 2004, 29, 998-1002.


1. WO2012149196A1.

2. US6514949B1.

3. Drugs of the Future 2004, 29, 998-1002.


1. WO2014068589A2.

Impurity database is being updated！